Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone

This study has been completed.
Sponsor:
Collaborators:
Millennium Pharmaceuticals, Inc.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00059631
First received: April 29, 2003
Last updated: June 19, 2015
Last verified: June 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2015
  Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)